- Home
- DATS vs MBRX Comparison
DATS vs MBRX Comparison
Compare DATS & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- MBRX
- Stock Information
- Founded
- DATS 2014
- MBRX 2015
- Country
- DATS United States
- MBRX United States
- Employees
- DATS N/A
- MBRX N/A
- Industry
- DATS Computer Software: Prepackaged Software
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- MBRX Health Care
- Exchange
- DATS Nasdaq
- MBRX Nasdaq
- Market Cap
- DATS 13.4M
- MBRX 12.9M
- IPO Year
- DATS 2021
- MBRX 2016
- Fundamental
- Price
- DATS $2.65
- MBRX $0.82
- Analyst Decision
- DATS
- MBRX Strong Buy
- Analyst Count
- DATS 0
- MBRX 3
- Target Price
- DATS N/A
- MBRX $5.33
- AVG Volume (30 Days)
- DATS 94.7K
- MBRX 13.1M
- Earning Date
- DATS 08-13-2025
- MBRX 08-13-2025
- Dividend Yield
- DATS N/A
- MBRX N/A
- EPS Growth
- DATS N/A
- MBRX N/A
- EPS
- DATS N/A
- MBRX N/A
- Revenue
- DATS $388.00
- MBRX N/A
- Revenue This Year
- DATS N/A
- MBRX N/A
- Revenue Next Year
- DATS N/A
- MBRX N/A
- P/E Ratio
- DATS N/A
- MBRX N/A
- Revenue Growth
- DATS N/A
- MBRX N/A
- 52 Week Low
- DATS $1.11
- MBRX $0.25
- 52 Week High
- DATS $9.34
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- DATS 48.57
- MBRX 71.04
- Support Level
- DATS $2.50
- MBRX $0.50
- Resistance Level
- DATS $2.71
- MBRX $0.73
- Average True Range (ATR)
- DATS 0.11
- MBRX 0.10
- MACD
- DATS -0.00
- MBRX 0.07
- Stochastic Oscillator
- DATS 41.46
- MBRX 94.61
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.